BioMedPartners
Investor profile
Venture capital
Also recorded as: BioMed Partners
Deals
15
distinct rounds
Companies
11
backed
Active span
2011–2024
14 yrs
Total round €
€435M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- GIMV4
- INKEF Capital3
- Pfizer Ventures3
- Coparion2
- Evotec2
- FundPlus2
- High-Tech Gründerfonds2
- Mission BioCapital2
- Sunstone Capital2
- Vesalius Biocapital Partners2
- VI Partners2
- Andera Partners1
- Bayern Kapital1
- BioGeneration Ventures1
- Boehringer Ingelheim Venture Fund1
- Bristol Myers Squibb1
- Double Point Ventures1
- Earlybird Venture Capital1
- EIR Ventures1
- EMBL Ventures1
- EntrePREneurs Fund1
- Epidarex Capital1
- Fiscus Financial1
- Forbion1
- GL Capital1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Immunos Therapeutics | Switzerland | 3 | €91M |
| Precirix | Belgium | 1 | €80M |
| Tubulis Technologies | Germany | 2 | €71M |
| Cardior Pharmaceuticals | Germany | 1 | €64M |
| Topas Therapeutics | Germany | 2 | €40M |
| Scenic Biotech | Netherlands | 1 | €28M |
| GenKyoTex | Switzerland | 1 | €19M |
| Anergis | Switzerland | 1 | €18M |
| Alentis Therapeutics | Switzerland | 1 | €11M |
| Sequana Medical | Switzerland | 1 | €8.5M |
| Miracor Medical Systems | Austria | 1 | €4.5M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Precirix | Series B | €80M | 2022-03 |
| Immunos Therapeutics | Series B | €68M | 2022-06 |
| Cardior Pharmaceuticals | Series B | €64M | 2021-08 |
| Tubulis Technologies | Series B | €60M | 2022-05 |
| Scenic Biotech | Series A | €28M | 2022-03 |
| Topas Therapeutics | Series B | €22M | 2020-10 |
| GenKyoTex | Series D+ | €19M | 2014-12 |
| Anergis | Series A | €18M | 2011-02 |
| Topas Therapeutics | Series B | €18M | 2021-07 |
| Immunos Therapeutics | Series A | €13M | 2019-09 |